PMID- 38356441
OWN - NLM
STAT- MEDLINE
DCOM- 20240417
LR  - 20240417
IS  - 1522-7278 (Electronic)
IS  - 1520-4081 (Linking)
VI  - 39
IP  - 5
DP  - 2024 May
TI  - Ellagic acid protects against angiotensin II-induced hypertrophic responses 
      through ROS-mediated MAPK pathway in H9c2 cells.
PG  - 3253-3263
LID - 10.1002/tox.24170 [doi]
AB  - The early myocardial response of hypertension is an elevation of angiotensin-II 
      (Ang-II) concentration, leading to heart failure and cardiac hypertrophy. This 
      hypertrophic event of the heart is mediated by the interaction of Ang type 1 
      receptors (AT-R1), thereby modulating NADPH oxidase activity in cardiomyocytes, 
      which alters redox status in cardiomyocytes. Ellagic acid (EA) has 
      anti-inflammatory and anti-oxidative capacities. Thus, EA has potential 
      preventive effects on cardiovascular diseases and diabetes. In the last decades, 
      because the protective effect of EA on Ang-II-induced hypertrophic responses is 
      unclear, this study aims to investigate the protective effect of EA in 
      cardiomyocytes. H9c2 cells were treated to Ang-II 1 muM for 24 h to induce 
      cellular damage. We found that EA protected against Ang-II-increased cell surface 
      area and pro-hypertrophic gene expression in H9c2. EA reduced Ang-II-caused AT-R1 
      upregulation, thereby inhibiting oxidative stress NADPH oxidase activation. EA 
      mitigated Ang-II-enhanced p38 and extracellular-signal-regulated kinase (ERK) 
      phosphorylation. Moreover, EA treatment under Ang-II stimulation also reversed 
      NF-kappaB activity and iNOS expression. This study shows that EA protects against 
      Ang-II-induced myocardial hypertrophy and attenuates oxidative stress through 
      reactive oxygen species-mediated mitogen-activated protein kinase signaling 
      pathways in H9c2 cells. Thus, EA may be an effective compound for preventing 
      Ang-II-induced myocardial hypertrophy.
CI  - (c) 2024 Wiley Periodicals LLC.
FAU - Lee, Ya-Che
AU  - Lee YC
AD  - Department of Urology, Ditmanson Medical Foundation Chiayi Christian Hospital, 
      Chia-Yi City, Taiwan.
FAU - Jou, Yeong-Chin
AU  - Jou YC
AD  - Department of Urology, St. Martin De Porres Hospital, Chia-Yi City, Taiwan.
AD  - Department of Health and Nutrition Biotechnology, College of Medical and Health 
      Science, Asia University, Taichung City, Taiwan.
FAU - Chou, Wan-Ching
AU  - Chou WC
AD  - Department of Physical Therapy, College of Medicine, National Cheng Kung 
      University, Tainan City, Taiwan.
FAU - Tsai, Kun-Ling
AU  - Tsai KL
AUID- ORCID: 0000-0002-3814-1453
AD  - Department of Physical Therapy, College of Medicine, National Cheng Kung 
      University, Tainan City, Taiwan.
AD  - Institute of Allied Health Science, College of Medicine, National Cheng Kung 
      University, Tainan City, Taiwan.
FAU - Shen, Cheng-Huang
AU  - Shen CH
AD  - Department of Urology, Ditmanson Medical Foundation Chiayi Christian Hospital, 
      Chia-Yi City, Taiwan.
AD  - Department of Biomedical Sciences, National Chung Cheng University, Min Hsiung, 
      Chia-Yi, Taiwan.
FAU - Lee, Shin-Da
AU  - Lee SD
AUID- ORCID: 0000-0002-8393-8349
AD  - Department of Physical Therapy, College of Medical and Health Science, Asia 
      University, Taichung City, Taiwan.
AD  - Department of Physical Therapy, PhD program in Healthcare Science, China Medical 
      University, Taichung, Taiwan.
LA  - eng
GR  - R109-039R/Chiayi Christian Hospital/
GR  - 109-39-1/Chiayi Christian Hospital/
GR  - R109-39-2/Chiayi Christian Hospital/
GR  - R109-39-3/Chiayi Christian Hospital/
PT  - Journal Article
DEP - 20240215
PL  - United States
TA  - Environ Toxicol
JT  - Environmental toxicology
JID - 100885357
RN  - 0 (Reactive Oxygen Species)
RN  - 11128-99-7 (Angiotensin II)
RN  - 19YRN3ZS9P (Ellagic Acid)
RN  - EC 1.6.3.- (NADPH Oxidases)
SB  - IM
MH  - Humans
MH  - Reactive Oxygen Species/metabolism
MH  - *Angiotensin II/pharmacology/metabolism
MH  - *Ellagic Acid/pharmacology
MH  - Myocytes, Cardiac
MH  - Cardiomegaly
MH  - NADPH Oxidases/metabolism/pharmacology
OTO - NOTNLM
OT  - MAPK
OT  - angiotensin-II
OT  - ellagic acid
OT  - myocardial hypertrophy
OT  - oxidative stress
EDAT- 2024/02/15 06:43
MHDA- 2024/04/17 06:42
CRDT- 2024/02/15 03:44
PHST- 2024/01/19 00:00 [revised]
PHST- 2023/10/13 00:00 [received]
PHST- 2024/01/26 00:00 [accepted]
PHST- 2024/04/17 06:42 [medline]
PHST- 2024/02/15 06:43 [pubmed]
PHST- 2024/02/15 03:44 [entrez]
AID - 10.1002/tox.24170 [doi]
PST - ppublish
SO  - Environ Toxicol. 2024 May;39(5):3253-3263. doi: 10.1002/tox.24170. Epub 2024 Feb 
      15.